Literature DB >> 3905458

Endogenous gut-derived bacterial endotoxin tonically primes pancreatic secretion of insulin in normal rats.

R P Cornell.   

Abstract

This laboratory has proposed that endogenous gut-derived bacterial endotoxin primes the pancreatic secretion of insulin in normal rats. Endogenous lipopolysaccharide (LPS) is continually absorbed from the gut into intestinal capillaries, and low-grade portal venous endotoxemia is the status quo. Under physiologic conditions, Kupffer cells of the liver totally phagocytize and degrade endotoxin from the portal circulation. Evidence from this and other laboratories indicates that administration of exogenous LPS to humans and rats enhances pancreatic secretion of both insulin and glucagon. Conversely, findings of the present study demonstrate that restriction of endogenous LPS in fasted rats depresses the basal and arginine-stimulated concentrations of plasma insulin. Techniques used to restrict gut-derived LPS availability included chronic daily gavage with neomycin and cefazolin for gut sterilization and with cholestyramine or lactulose to reduce endotoxin within the gut. In addition, induction of endotoxin tolerance was produced by progressively higher doses of LPS intraperitoneally (i.p.), and polymyxin B was administered subcutaneously (s.c.) daily to neutralize the lipid A portion of circulating LPS. Finally, isolator-reared, defined flora rats, which were gram-negative-bacteria-deficient, and, therefore, LPS-deficient, were compared with conventional counterparts. Basal plasma insulin but not glucagon levels were consistently and significantly reduced in endogenous LPS-restricted animals. Glucose-stimulated plasma insulin was decreased only after parenteral treatment by tolerance induction and polymyxin B administration. Both plasma insulin and glucagon were depressed in response to arginine challenge in most LPS-restricted rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3905458     DOI: 10.2337/diab.34.12.1253

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  Lipopolysaccharide inhibition of glucose production through the Toll-like receptor-4, myeloid differentiation factor 88, and nuclear factor kappa b pathway.

Authors:  Carl F Raetzsch; Natasha L Brooks; J McKee Alderman; Kelli S Moore; Peter A Hosick; Simon Klebanov; Shizuo Akira; James E Bear; Albert S Baldwin; Nigel Mackman; Terry P Combs
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

2.  Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of Langerhans.

Authors:  G A Spinas; B S Hansen; S Linde; W Kastern; J Mølvig; T Mandrup-Poulsen; C A Dinarello; J H Nielsen; J Nerup
Journal:  Diabetologia       Date:  1987-07       Impact factor: 10.122

3.  Endotoxin Biomarkers Are Associated With Adiposity and Cardiometabolic Risk Across 6 Years of Follow-up in Youth.

Authors:  Wei Perng; Jacob E Friedman; Rachel C Janssen; Deborah H Glueck; Dana Dabelea
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

Review 4.  Epidemiological Research Advances in Vascular Calcification in Diabetes.

Authors:  Haipeng Yao; Zhen Sun; Guangyao Zang; Lili Zhang; Lina Hou; Chen Shao; Zhongqun Wang
Journal:  J Diabetes Res       Date:  2021-10-01       Impact factor: 4.011

Review 5.  The potential role of lactulose pharmacotherapy in the treatment and prevention of diabetes.

Authors:  Natural Chu; James Ling; He Jie; Kathy Leung; Emily Poon
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

6.  The toll-like receptor signaling molecule Myd88 contributes to pancreatic beta-cell homeostasis in response to injury.

Authors:  Paul L Bollyky; Jeffrey B Bice; Ian R Sweet; Ben A Falk; John A Gebe; April E Clark; Vivian H Gersuk; Alan Aderem; Thomas R Hawn; Gerald T Nepom
Journal:  PLoS One       Date:  2009-04-01       Impact factor: 3.240

7.  The parotid secretory protein BPIFA2 is a salivary surfactant that affects lipopolysaccharide action.

Authors:  Seshagiri Rao Nandula; Ian Huxford; Thomas T Wheeler; Conrado Aparicio; Sven-Ulrik Gorr
Journal:  Exp Physiol       Date:  2020-06-19       Impact factor: 2.858

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.